109 related articles for article (PubMed ID: 7554039)
21. Comparison of tropisetron and chlorpromazine combinations in the control of nausea and vomiting of patients with advanced cancer.
Mystakidou K; Befon S; Liossi C; Vlachos L
J Pain Symptom Manage; 1998 Mar; 15(3):176-84. PubMed ID: 9564119
[TBL] [Abstract][Full Text] [Related]
22. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
23. Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies.
Otten J; Hachimi-Idrissi S; Balduck N; Maurus R
Semin Oncol; 1994 Oct; 21(5 Suppl 9):17-9. PubMed ID: 9113122
[TBL] [Abstract][Full Text] [Related]
24. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
25. The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens.
du Bois A; Vach W; Siebert C; Holy R; Ledergerber M; Wechsel U; Kriesinger-Schroeder H
Support Care Cancer; 1997 May; 5(3):212-8. PubMed ID: 9176967
[TBL] [Abstract][Full Text] [Related]
26. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
27. Tropisetron, a new 5-HT3 receptor antagonist, in the prevention of radiation-induced emesis.
Sorbe B; Berglind AM; de Bruijn K
Radiother Oncol; 1992 Feb; 23(2):131-2. PubMed ID: 1546189
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacological review of tropisetron].
Yokoyama T
Nihon Yakurigaku Zasshi; 1999 Oct; 114(4):219-26. PubMed ID: 10584235
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
30. Tropisetron: optimal dosage for children in prevention of chemotherapy-induced vomiting.
Cappelli C; Ragni G; De Pasquale MD; Gonfiantini M; Russo D; Clerico A
Pediatr Blood Cancer; 2005 Jul; 45(1):48-53. PubMed ID: 15768378
[TBL] [Abstract][Full Text] [Related]
31. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
32. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
Castejon AM; Paez X; Hernandez L; Cubeddu LX
J Pharmacol Exp Ther; 1999 Dec; 291(3):960-6. PubMed ID: 10565811
[TBL] [Abstract][Full Text] [Related]
33. Ambulatory infusion of bleomycin in patients receiving chemotherapy for germ cell tumors.
Green JA; Hammond P; Watkin SW
Sel Cancer Ther; 1989; 5(2):93-5. PubMed ID: 2475900
[No Abstract] [Full Text] [Related]
34. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Malave JJ
Br J Cancer; 1992 Jul; 66(1):198-203. PubMed ID: 1379060
[TBL] [Abstract][Full Text] [Related]
35. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis.
Leibundgut U; Lancranjan I
Lancet; 1987 May; 1(8543):1198. PubMed ID: 2883502
[No Abstract] [Full Text] [Related]
36. Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis.
Garbe C; Drechsler S; Fiedler H; Tilgen W; Landthaler M; Schroeder K; Kuehne KH; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):12-6. PubMed ID: 9113121
[TBL] [Abstract][Full Text] [Related]
37. Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy.
Pisters KM; Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1993 Jan; 71(1):226-30. PubMed ID: 8416720
[TBL] [Abstract][Full Text] [Related]
38. Tropisetron. A review of the clinical experience.
de Bruijn KM
Drugs; 1992; 43 Suppl 3():11-22. PubMed ID: 1380428
[TBL] [Abstract][Full Text] [Related]
39. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
Kris MG; Grunberg SM; Gralla RJ; Baltzer L; Zaretsky SA; Lifsey D; Tyson LB; Schmidt L; Hahne WF
J Clin Oncol; 1994 May; 12(5):1045-9. PubMed ID: 8164028
[TBL] [Abstract][Full Text] [Related]
40. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients.
Alfieri AB; Cubeddu LX
Br J Cancer; 1995 Mar; 71(3):629-32. PubMed ID: 7533519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
